At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
ranibizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD
In Brief
A Phase 4 clinical trial evaluating ranibizumab and Conbercept for Age-related Macular Degeneration. Completed, enrolled 12 participants across 1 site.
Detailed Summary
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular age-related macular degeneration
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-related Macular Degeneration
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJan 2016
Primary CompletionJul 2016
TodayJul 2026
First PostedOct 16, 2015
Enrollment StartJan 13, 2016
Primary CompletionJul 9, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.7 years ago
Interventions
ranibizumabdrug
Conberceptdrug